‘Nesina Act’ that improved the fundamental cause of diabetes is expected to shake the market

The first complex of alogliptin and a TZD type composite, ‘Nesina Act’, has attracted attention.

Takeda Pharmaceuticals Korea unveiled at the press conference on 11^th that the new drug ‘Nesina Act’, having the DDP-4 inhibitor ‘Nesina (generic name: alogliptin)’ and the thiazolidinedione (TZD) type drug ‘Actos (generic name: pioglitazone)’ as main composites, had an approval from the Ministry o...